Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/10412
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBerkovic, Samuel Fen
dc.contributor.authorKnowlton, R Cen
dc.contributor.authorLeroy, R Fen
dc.contributor.authorSchiemann, Jen
dc.contributor.authorFalter, Uen
dc.date.accessioned2015-05-15T23:51:15Z
dc.date.available2015-05-15T23:51:15Z
dc.date.issued2007-07-11en
dc.identifier.citationNeurology 2007; 69(18): 1751-60en
dc.identifier.govdoc17625106en
dc.identifier.otherPUBMEDen
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/10412en
dc.description.abstractTo assess the efficacy and tolerability of adjunctive levetiracetam in patients with uncontrolled generalized tonic-clonic (GTC) seizures associated with idiopathic generalized epilepsies (IGE).This multicenter, randomized, double-blind, placebo-controlled, parallel-group study enrolled adults and children (4 to 65 years) with IGE experiencing >or=3 GTC seizures during the 8-week baseline period (4-week retrospective and 4-week prospective), despite receiving stable doses of one or two antiepileptic drugs (AEDs). Patients were randomized to levetiracetam (target dose 3,000 mg/day for adults; 60 mg/kg/day for children) or placebo and a 4-week titration period was followed by a 20-week evaluation period.Of 229 patients screened, 164 were randomized (levetiracetam, n = 80; placebo, n = 84). Levetiracetam produced a greater mean reduction in GTC seizure frequency per week over the treatment period (56.5%) than placebo (28.2%; p = 0.004). The percentage of patients who had >or=50% reduction of GTC seizure frequency per week (responders) during the treatment period was 72.2% for levetiracetam and 45.2% for placebo (p < 0.001; OR 3.28; 95% CI 1.68 to 6.38). During the first 2-week treatment 64.6% of patients on levetiracetam and 45.2% on placebo (p = 0.018) were classified as responders. During the evaluation period the percent of patients free of GTC seizures (34.2% vs 10.7%; p < 0.001) and all seizure types (24.1% vs 8.3%; p = 0.009) was greater for levetiracetam than placebo. Levetiracetam was well tolerated with 1.3% of patients discontinuing therapy due to adverse events vs 4.8% on placebo.Adjunctive levetiracetam is an effective and well-tolerated antiepileptic drug for treating generalized tonic-clonic seizures in patients with idiopathic generalized epilepsies.en
dc.language.isoenen
dc.subject.otherAdolescenten
dc.subject.otherAdulten
dc.subject.otherAgeden
dc.subject.otherAnticonvulsants.therapeutic useen
dc.subject.otherChilden
dc.subject.otherChild, Preschoolen
dc.subject.otherDouble-Blind Methoden
dc.subject.otherEpilepsy, Generalized.drug therapyen
dc.subject.otherFemaleen
dc.subject.otherHumansen
dc.subject.otherMaleen
dc.subject.otherMiddle Ageden
dc.subject.otherPiracetam.analogs & derivatives.therapeutic useen
dc.subject.otherPlacebosen
dc.subject.otherQuality of Lifeen
dc.subject.otherQuestionnairesen
dc.subject.otherResearch Designen
dc.subject.otherTreatment Outcomeen
dc.titlePlacebo-controlled study of levetiracetam in idiopathic generalized epilepsy.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeurologyen
dc.identifier.affiliationEpilepsy Research Center, Heidelberg Repatriation Hospital, Banksia Street, West Heidelberg, Victoria, Australiaen
dc.identifier.doi10.1212/01.wnl.0000268699.34614.d3en
dc.description.pages1751-60en
dc.relation.urlhttps://pubmed.ncbi.nlm.nih.gov/17625106en
dc.contributor.corpauthorLevetiracetam N01057 Study Groupen
dc.type.austinJournal Articleen
local.name.researcherBerkovic, Samuel F
item.openairetypeJournal Article-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.grantfulltextnone-
item.fulltextNo Fulltext-
item.cerifentitytypePublications-
item.languageiso639-1en-
crisitem.author.deptEpilepsy Research Centre-
crisitem.author.deptNeurology-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

28
checked on Mar 27, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.